Efungumab

Efungumab^?
Therapeutic monoclonal antibody
Source	Human
Target	Fungal Hsp90
Identifiers
CAS number	?
ATC code	?
PubChem	?
Chemical data
Formula	?
Mol. mass	?
Pharmacokinetic data
Bioavailability	Not applicable (IV only)
Protein binding	High
Metabolism	?
Half life	1–2 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Intravenous

Efungumab (trade name Mycograb) is a human monoclonal antibody developed by NeuTec Pharma (a subsidiary of Novartis), intended to treat invasive Candida infection in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.^[1]

[edit] References

^ European Medicines Agency (2007). REFUSAL CHMP ASSESSMENT REPORT FOR MYCOGRAB. Procedure No. EMEA/H/C/658PDF (370 KiB). London: European Medicines Agency. Retrieved on 2007-11-20. Detailed assessment report with comprehensive overview of reasons for refusal of marketing authorization.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

v • d • e Human monoclonal antibodies ("-u-")

"-limu-" (immune system)	immunosuppression: Adalimumab, Atorolimumab, Gantenerumab, Golimumab, Lerdelimumab, Metelimumab, Morolimumab, Ziralimumab immune activation: Ipilimumab, Tremelimumab other: Bertilimumab

"-kinu-" (interleukin as target)	Canakinumab

"-tumu-" (cancer immunotherapy)	Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab

"-osu-" (bone)	Denosumab

"-mulu-" (musculoskeletal)	Durimulumab, Durmulumab, Stamulumab

"-fungu-" (fungal)	Efungumab

"-viru-" (viral)	Exbivirumab, Libivirumab, Regavirumab, Sevirumab, Tuvirumab

"-bacu-" (bacterial)	Nebacumab, Raxibacumab